Stanley L Liauw

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 4

Top Topics

Benign Prostatic Hyperplasia

Venous Thromboembolism

Prostate Cancer

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

JNCI cancer spectrum

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Phuoc T Tran, Kathryn Lowe, Hua-Ling Tsai, Daniel Y Song, Arthur Y Hung, Jason W D Hearn, Steven Miller, James A Proudfoot, Matthew P Deek, Ryan Phillips, Tamara Lotan, Channing J Paller, Catherine Handy Marshall, Mark C Markowski, Shirl Dipasquale, Samuel R Denmeade, Michael Carducci, Mario A Eisenberger, Theodore L DeWeese, Matthew Orton, Curtiland Deville, Elai Davicioni, Stanley L Liauw, Elisabeth I Heath, Stephen Greco, Neil B Desai, Daniel E Spratt, Felix Y Feng, Hao Wang, Tomasz M Beer, Emmanuel S Antonarakis
Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Benjamin E Onderdonk, Paige L Dorn, Carlos Martinez, Fauzia Arif, Denise Cloutier, Tatjana Antic, Daniel W Golden, Theodore Karrison, Sean P Pitroda, Russell Z Szmulewitz, Stanley L Liauw
A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. Cancer 127 (15) (2021)
William Tyler Turchan, Stanley I Gutiontov, Michael T Spiotto, Stanley L Liauw
Prostate Cancer Radiotherapy: Increased Biochemical Control and Late Toxicity in Men With Medication Allergies. JNCI cancer spectrum 4 (6) (2020)
Stanley I Gutiontov, Kevin S Choe, Jonathan L Miller, Stanley L Liauw
Improved outcomes after radiotherapy for prostate cancer: Anticoagulation, antiplatelet therapy, and platelet count as key factors in disease progression. Cancer medicine 9 (13) (2020)